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TECHNOLOGY ASSESSMENT

Devices for endoscopic hemostasis of nonvariceal GI bleeding
(with videos)
Prepared by: ASGE TECHNOLOGY COMMITTEE
Mansour A. Parsi, MD, MPH, FASGE,1 Allison R. Schulman, MD, MPH,2 Harry R. Aslanian, MD, FASGE,3
Manoop S. Bhutani, MD, FASGE,4 Kuman Krishnan, MD,5 David R. Lichtenstein, MD, FASGE,6
Joshua Melson, MD, FASGE,7 Udayakumar Navaneethan, MD,8 Rahul Pannala, MD, MPH, FASGE,9
Amrita Sethi, MD, FASGE,10 Guru Trikudanathan, MD,11 Arvind J. Trindade, MD,12
Rabindra R. Watson, MD,13 John T. Maple, DO, FASGE,14 ASGE Technology Committee Chair
This document was reviewed and approved by the Governing Board of the American Society for Gastrointestinal
Endoscopy (ASGE).

Background: Endoscopic intervention is often the ﬁrst line of therapy for GI nonvariceal bleeding. Although
some of the devices and techniques used for this purpose have been well studied, others are relatively new,
with few available outcomes data.
Methods: In this document, we review devices and techniques for endoscopic treatment of nonvariceal GI
bleeding, the evidence regarding their efﬁcacy and safety, and ﬁnancial considerations for their use.
Results: Devices used for endoscopic hemostasis in the GI tract can be classiﬁed into injection devices (needles),
thermal devices (multipolar/bipolar probes, hemostatic forceps, heater probe, argon plasma coagulation, radiofrequency ablation, and cryotherapy), mechanical devices (clips, suturing devices, banding devices, stents), and
topical devices (hemostatic sprays).
Conclusions: Endoscopic evaluation and treatment remains a cornerstone in the management of nonvariceal
upper- and lower-GI bleeding. A variety of devices is available for hemostasis of bleeding lesions in the GI tract.
Other than injection therapy, which should not be used as monotherapy, there are few compelling data that
strongly favor any one device over another. For endoscopists, the choice of a hemostatic device should depend
on the type and location of the bleeding lesion, the availability of equipment and expertise, and the cost of the
device. (VideoGIE 2019;4:285-99.)

INTRODUCTION
The American Society for Gastrointestinal Endoscopy
(ASGE) Technology Committee provides reviews of existing, new, or emerging endoscopic technologies that have
an impact on the practice of GI endoscopy. Evidencebased methodology is used, with a MEDLINE literature
search to identify pertinent clinical studies on the topic
and a MAUDE (U.S. Food and Drug Administration Center
Copyright ª 2019 by the American Society for Gastrointestinal Endoscopy.
Published by Elsevier, Inc. This is an open access article under the CC BY-NCND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
https://doi.org/10.1016/j.vgie.2019.02.004
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for Devices and Radiological Health) database search to
identify the reported adverse events of a given technology.
Both are supplemented by accessing the “related articles”
feature of PubMed and by scrutinizing pertinent references
cited by the identiﬁed studies. Controlled clinical trials are
emphasized, but in many cases, data from randomized
controlled trials (RCTs) are lacking. In such cases, large
case series, preliminary clinical studies, and expert opinions are used. Technical data are gathered from traditional
and Web-based publications, proprietary publications, and
informal communications with pertinent vendors. Technology Status Evaluation Reports are drafted by 1 or 2 members of the ASGE Technology Committee, reviewed and
edited by the committee as a whole, and approved by
the Governing Board of the ASGE. When ﬁnancial
Volume 4, No. 7 : 2019 GASTROINTESTINAL ENDOSCOPY 285
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guidance is indicated, the most recent coding data and list
prices at the time of publication are provided. For this review, the MEDLINE database was searched through
September 2017 for articles related to endoscopic hemostasis devices by using relevant keywords such as “gastrointestinal bleeding,” “GI bleeding,” “nonvariceal bleeding,”
“endoscopic hemostasis,” and “endoscopic treatment,”
among others. Technology Status Evaluation Reports are
scientiﬁc reviews provided solely for educational and informational purposes. Technology Status Evaluation Reports
are not rules and should not be construed as establishing
a legal standard of care or as encouraging, advocating,
requiring, or discouraging any particular treatment or payment for such treatment.

BACKGROUND
Endoscopic intervention is often the ﬁrst line of therapy
for upper- and lower-GI nonvariceal bleeding. Devices
used for endoscopic hemostasis in the GI tract can be classiﬁed into injection devices (needles), thermal devices
(multipolar/bipolar probes, hemostatic forceps, heater
probe, argon plasma coagulation, radiofrequency ablation
and cryotherapy), mechanical devices (clips, suturing devices, banding devices, stents), and topical devices (hemostatic sprays). This document describes technologies used
for endoscopic hemostasis. Cryotherapy and radiofrequency ablation were described in detail in separate recent
ASGE Technology assessments and are not reviewed in this
document.1,2

TECHNOLOGY UNDER REVIEW
Injection needles
Injection needles consist of an outer sheath made of
plastic, polytetraﬂuoroethylene (PTFE, Teﬂon), or stainless
steel, an inner hollow-core needle (19-25 gauge), and a
handle. The handle is used to manipulate the needle in
or out of the outer sheath. The handle includes a Luer
lock connector for a syringe attachment. The needle is
kept within the sheath for safe advancement through the
working channel of the endoscope. When the target is
reached, the outer sheath is advanced beyond the endoscope tip, and the needle is extended to a preset distance.
A syringe is then attached to the handle to inject liquid
agents into the target tissue.3 Injection of various
solutions achieves hemostasis by mechanical tamponade
and/or cytochemical mechanisms. Injection needles of
various lengths and diameters have been developed for
endoscopic hemostasis in the GI tract (Table 1).

Thermal devices
Endoscopic hemostasis can be achieved by the application of heat or cold at the site of bleeding. Heat causes hemostasis by inducing edema, protein coagulation,
286 GASTROINTESTINAL ENDOSCOPY Volume 4, No. 7 : 2019

vasoconstriction, and indirect activation of the coagulation
cascade.3 Tissue coagulation by heat requires a
temperature of approximately 70 C.3 Thermal devices
used for endoscopic hemostasis in the GI tract have
traditionally been divided into contact (bipolar/multipolar
electrocautery, heater probe, and hemostatic forceps)
and noncontact devices (argon plasma coagulation)
(Tables 2 and 3).
Bipolar/multipolar electrocoagulation probes.
Hemostasis using electric current passing through a probe
to generate heat can be performed using either a monopolar or a multipolar electrocoagulation (MPEC) device.4
With monopolar devices, the current passes through the
patient and back to the unit via a return pad, whereas
with MPEC devices, the electric current is conﬁned to
the tissue between the electrodes within the instrument
tip, obviating the need for a return pad.4,5
The MPEC probe can be used tangentially to, or perpendicularly to, the bleeding source. Pressure is applied to
compress and seal the walls of the bleeding vessel (“coaptive coagulation”).6 MPEC probes are available in 7F and
10F diameters with an irrigation port at the tip; the 10F
probe requires the use of an endoscope with a 3.2 mm
diameter instrument channel. Probe size, wattage,
contact pressure and duration, and number of
applications will vary depending on the lesion being
treated.
Heater probe. The heater probe comprises a PTFE–
coated hollow aluminum cylinder with an inner heating
coil and an irrigation port at the tip of a 230- to 300-cm
7F to 10F catheter.3 The probes are reusable and are
compatible with the HPU-20 (Olympus America, Center
Valley, Pa, USA) power source. The probe transfers heat
from its end or sides, causing tissue coagulation. The
PTFE coating reduces adherence of the probe to tissue.7
The probe is placed directly at the site of the bleeding
vessel, either perpendicularly or tangentially, with
pressure applied for coaptive coagulation. A foot pedal
controls heat activation and irrigation. Once the pulse
has been initiated, the duration of activation is
predetermined and will deliver the entire amount of
preselected energy.3 A power setting of 25 J to 30 J per
pulse, using 4 to 5 pulses (total of 100-150 J) per station
(before the probe position is changed) has been
recommended for peptic ulcer bleeding.7 Of note, sales
of the HPU-20 in the United States were discontinued in
2011, and the manufacturer has communicated its intention to discontinue sales of the compatible probes in
2019 (personal communication).
Hemostatic forceps. Hemostatic forceps are devices
that were developed initially for treatment and prevention
of bleeding during endoscopic resection (Fig. 1). The
bleeding tissue is grasped within the jaws of the forceps,
and electrocoagulation is used to coagulate the bleeding
source; retraction of the tissue will limit the depth of
coagulation injury. Hemostatic forceps are available from
www.VideoGIE.org
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TABLE 1. Injection needles

Manufacturer
Boston Scientific (Natick,
Mass, USA)
Medtronic Endoscopic
Technologies
(Chelmsford,
Mass, USA)

Cook Medical
(Winston-Salem,
NC, USA)

Halyard Health
(Roswell, Ga, USA)
Olympus America (Center
Valley, Pa, USA)
US Endoscopy (Mentor,
Ohio, USA)

Device name

Sheath
diameter
(French)

Sheath
length
(cm)

Needle
gauge

Needle
length
(mm)

List price

Inject sclerotherapy needle

7

200, 240

23, 25

4, 6

$70 each

Click-tip injection needle

7

180, 230

19,

4, 6

$743.88/
box of 10

180, 230

22, 25

4, 6

$704.64/
box of 10

FlexiTip disposable
sclerotherapy needle - standard

7

160, 230

25

4, 5, 6

$294.6/
box of 5

FlexiTip disposable sclerotherapy
needle - optic yellow tip

7

160, 230

25

4, 5, 6

$362.5/
box of 5

AcuJect variable
injection needle

7

220

23, 25

Variable

$51 each

Disposable varices
injector

7

200-320

23, 25

Variable

$62-86 each

7

220

23, 25

Variable

$61 each

Injection needle
catheter

7

160, 200, 240

23, 25

4, 6

$318.94/
box of 10

Injector Force Max
injection needle

7

165-230

www.VideoGIE.org

Visible in
bloody field

Flush port

21, 23, 25 4, 5, 6, 8 $433.50 (21G)/
box of 5

Articulator Injection needle

7

160, 230, 350

25

4, 5

$53/box of 5

Carr-Locke injection needle

7

230

25

5

$63/box of 5

iSnare

10

230

23, 25

5

$139/box of 5

multiple manufacturers: Olympus Coagrasper, Fujiﬁlm
Clutch Cutter (Fujiﬁlm Medical Systems USA, Inc,
Stamford, Conn, USA), Sumitomo Bakelite SB Knife
(Sumitomo Bakelite Co, Ltd, Tokyo, Japan) and vary in
features including jaw shape, opening width, rotatability,
and working length. Use of electrosurgical current
waveforms in which the peak voltage is held below 200
volts, such as Soft Coag mode with the Erbe Vio 300 unit
(Erbe USA, Inc, Marietta, Ga, USA) or TouchSoft mode
with the gi4000 unit (US Endoscopy, Mentor, Ohio, USA)
has been described when using hemostatic forceps.8-10 Hemostatic forceps that have been cleared by the U.S. Food
and Drug Administration (FDA) are monopolar devices; bipolar devices have been developed but are not currently
available in the United States.11,12
Argon plasma coagulation. Argon plasma coagulation (APC) is a noncontact thermal method of hemostasis.
An APC delivery system consists of an argon gas cylinder, a
computer-controlled,
high-frequency
electrosurgical
generator with a gas ﬂow-controlling valve, and an endoscopic probe.4 Inert argon gas is converted to ionized
argon gas (plasma) by a monopolar electrode at the tip
of the probe. The probe tip is placed close to the
bleeding lesion, with the optimal distance ranging from 2
to 8 mm.3 High-frequency monopolar current is then conducted through the gas, resulting in tissue coagulation.

Special
features

2.5-  4-cm
integrated snare

Variables of system setup include power (watts), gasﬂow rate, and mode of energy delivery.4 Increased power
results in more rapid devitalization of tissue and deeper
penetration. Gas ﬂow should be set at the lowest
possible rate for desired tissue effect to reduce the risk
of gas embolization and argon-related pneumoperitoneum.4 The mode of current delivery can be set to either
forced or pulsed. Forced mode entails continuous
delivery of energy, resulting in more rapid tissue
devitalization and hemostasis. By contrast, pulsed mode
sends intermittent bursts of energy to the tissue,
resulting in a more superﬁcial effect.4 APC is particularly
well suited for superﬁcial treatments because the
penetration depth of the coagulation is limited to only a
few millimeters.13 APC probes are available in a variety of
lengths and diameters with forward, side, or
circumferential ports allowing forward, tangential, or
circumferential applications, respectively.3

Mechanical devices
Clips. Clips are metallic devices that effect hemostasis
by mechanical approximation of tissue and subsequent
tamponade. Two broad categories of clips are currently
available for endoscopic hemostasis in the GI tract:
through-the-scope (TTS) clips and cap-mounted clips.
Volume 4, No. 7 : 2019 GASTROINTESTINAL ENDOSCOPY 287
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TABLE 2. Contact thermal devices

Manufacturer

Device name

Sheath
diameter
(French)

Sheath
length
(cm)

List price

Gold probe

7, 10

300, 350

$359

Injector gold probe

7, 10

210

$519

Bicap superconductor,
multielectrode bipolar
probe

5, 7, 10

200, 300, 350

$396.48

7. 10

300

$240

Quicksilver bipolar
probe

7, 10

350

$328

BiCOAG bipolar
probe

7, 10

350

$370.30

7, 10

350

Bipolar hemostasis
probe

7, 10

350

$300

HeatProbe

7, 10

230, 300

$812

Reusable

Coagrasper (upper/gastric)

7

165

$278

Opening width 5 or
6.5 mm
Rotatable

Coagrasper (lower)

7

230

$320

Opening width
4 mm
Rotatable

SB Knife (Jr, Short, Standard)

7

230, 195, 180

$1695

JR: opening width
4.5 mm; scissor-like jaw
Short: opening width
6 mm, angled tip design
Standard: opening width
8 mm, angled tip design
Rotatable

ClutchCutter

7

180

$670

Serrated, rotatable jaws

Special features

Multipolar electrocautery probes
Boston Scientific (Natick, Mass, USA)

Medtronic Endoscopic Technologies
(Chelmsford, Mass, USA)
Cook Medical (Winston-Salem,
NC, USA)
Olympus America (Center Valley,
Pa, USA)
US Endoscopy (Mentor,
Ohio, USA)

Integrated 25-gauge
injection needle

Bipolar coagulation provides
coagulation at any angle

Heater probes
Olympus America (Center Valley,
Pa, USA)
Hemostatic grasper
Olympus America (Center Valley,
Pa, USA)

Fujifilm Medical Systems
(Wayne, NJ, USA)

TABLE 3. Noncontact thermal devices

Manufacturer

Device name

Sheath
diameter
(French)

Sheath
length
(cm)

Fire direction

List price

Canady (Hampton, Va, USA)

Canady plasma
GI probe

5, 7

230, 340

Straight, side

$1650/box of 10
$165/probe

Medtronic Endoscopic Technologies
(Chelmsford, Mass, USA)

Beamer argon
probe

5, 7, 10

160, 230, 320

Straight, fire

$3202.80/box of 10

Beamer argon
snare probe

7

160, 230

Straight, fire

$2241.60/box of 5

APC probe

5, 7, 10

150, 220, 300

Straight, side,
circumferential

FiAPC probe

5, 7, 10

150, 220, 300

Straight, side,
circumferential

ERBE USA, Inc. (Marietta, Ga, USA)

$2139.50 to
2459.50/box of 10*
$2139.50 to
2459.50/box of 10y

Special features

Combination APC
probe and snare

Integrated filter

*Endoscopy size.
yEndoscope cap depth.
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Figure 1. Colonic (left) and gastric (right) Coagrasper hemostatic forceps. (Image used with permission from Gastrointest Endosc 2015;81:1311-25.)

TTS clips were speciﬁcally developed for endoscopic hemostasis in the GI tract and have been in use for many
years (Video 1, available online at www.VideoGIE.org).
They are composed of 3 main components: a metallic
double-pronged clip, a delivery catheter, and a handle
used to operate and deploy the clip.3 The orientation of
some clips can be adjusted by rotating the handle itself
or a component of the handle. Some clips can be
reopened after initial closure before deployment. TTS
clips of various sizes and lengths are commercially
available (Table 4).
Cap-mounted clips were developed for endoscopic
closure of GI perforations and ﬁstulae, but they also have utility in hemostasis. Compared with TTS clips, cap-mounted
clips are able to compress a larger amount of tissue.14
Currently, 2 cap-mounted clip systems are commercially
available; the over-the-scope clip system (OTSC, Ovesco
Endoscopy AG, Tübingen, Germany) and the Padlock system
(US Endoscopy) (Fig. 2). Both systems are cleared by the
FDA for hemostatic indications.15
The OTSC system comprises an application cap with a
preloaded nitinol clip that is mounted onto the distal tip
of an endoscope. The mounted clip is attached to a
rotating wheel installed on the handle of the scope by a
string that runs through the instrument channel of the
endoscope. Rotating the wheel on the handle releases
the clip from the cap. The setup and deployment of these
clips is similar to band ligators used to treat esophageal
varices. Three variants of the clip are available, with
differing conﬁgurations of the tissue-grasping teeth: type
www.VideoGIE.org

a (atraumatic), type t (traumatic), and type gc (gastric ﬁstula closure).14 The type a clip is marketed for
hemostasis applications. The clips are available in 3 sizes,
with the variation corresponding to different diameters of
the application cap, which is necessary for compatibility
with a range of endoscope outer diameters (8.5 mm to
14.5 mm). Two proprietary devices are available to
further retract tissue into the cap if needed: a dual-arm forceps (“OTSC Twin Grasper”) and a tissue anchoring tripod
(“OTSC Anchor”).16
The Padlock system consists of an application cap with a
preloaded nitinol clip that is mounted onto the distal tip of
an endoscope and is attached to a releasing mechanism
installed on the handle of the scope by a linking cable.
As opposed to the OTSC system, the linking cable runs
outside the scope, not within the instrument channel.15
This design theoretically may allow for more efﬁcient
suction of tissue into the cap.15 The Padlock system is
available in 2 options: “Padlock Clip” for endoscopes
between 9.5 mm and 11 mm in outer diameter, and
“Padlock Clip Pro-Select” for endoscopes between
11.5 mm and 14 mm in outer diameter.17
Endoscopic suturing devices. An endoscopic suturing device (OverStitch, Apollo Endosurgery, Austin, Tex,
USA) is currently available for clinical use. The primary applications of this device are perforation closure and bariatric treatment.15 It is FDA cleared for soft tissue
approximation.15 Use of this device for attaining
hemostasis in bleeding gastric and anastomotic ulcers has
been described.18,19
Volume 4, No. 7 : 2019 GASTROINTESTINAL ENDOSCOPY 289
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TABLE 4. Mechanical hemostatic devices

Manufacturer
Boston Scientific
(Natick, Mass, USA)

Device name

Sheath
diameter
(French)

Sheath
length
(cm)

Jaw opening
width (mm)

List price

Resolution Clip

7

155, 235

11

$330/each

Resolution 360 Clip

7

155, 235

11

$370/each

Special features
Open/close jaw
up to 5 times
MR conditional up
to 3 Tesla
Open/close jaw
up to 5 times
MR conditional
up to 3 Tesla
Controlled rotation in
tortuous anatomy
Can be rotated by
technician or endoscopist

QuickClip2

7

165, 230

9

QuickClip2 long

7

165, 230

11

$713/box of 5
$2726/box of 20

QuickClip Pro

7

165, 230

11

$3714/box of 10

Precise rotation
MR conditional
up to 3 Tesla

Cook Medical (WinstonSalem, NC, USA)

Instinct

7

207

16

$2621/box of 10

Open/close jaw
up to 5 times
MR conditional
up to 3 Tesla

ConMed (Utica, NY, USA)

Dura Clip

7

165, 235

11

$3000/box of 10

Shorter clip design,
closer proximity to
tissue defect
Unlimited open/close
before deployment
MR conditional
up to 3 Tesla

$1250/box of 10

Shorter clip design
Unlimited open/close
before deployment
MR conditional
up to 3 Tesla
Blunt or pointed teeth
Blunt or pointed teeth
Blunt or pointed teeth

Olympus America
(Center Valley, Pa, USA)

Micro-Tech Endoscopy
USA (Ann Arbor,
Mich, USA)

SureClip

7

165, 235

11

SureClip plus

7

235

16

Ovesco Endoscopy USA
Inc (Carey, NC, USA)

Over-the-scopeclip (OTSC)

8.5 to 11 mm*

165

3, 6y

$438

10.5 to 12 mm*

165, 220

3, 6y

$543 (3 mm)
$589 (6 mm)

11.5 to 14 mm*

220

3, 6y

$610

US endoscopy (Mentor,
Ohio, USA)

Padlock Clip

9.5 to 11 mm*

165

10z

$599

Padlock Clip
Pro-Select

11.5 to 14 mm*

165

4 to 14z

$599

*Endoscopy size.
yEndoscope cap depth.
zTissue chamber depth.

The OverStitch device requires a double-channel endoscope (compatible only with Olympus scopes GIF-2T160
or GIF-2T180; Olympus Corporation, Tokyo, Japan) and
consists of a suture anchor with a detachable needle tip
carrying absorbable (2-0 or 3-0 polydioxanone) or nonabsorbable (2-0 or 3-0 polypropylene) sutures.15,20,21 This device is described in detail in an ASGE technology
assessment titled Endoscopic Closure Devices.22
Banding Devices. Endoscopic band ligation (EBL) is a
well-established therapy for bleeding esophageal varices,
290 GASTROINTESTINAL ENDOSCOPY Volume 4, No. 7 : 2019

but it also has utility in the treatment of nonvariceal
bleeding.23 Endoscopic banding devices consist of a
transparent cap, a connecting wire or string, and a
handle. The cap is mounted on the distal end of the
endoscope and carries 4 to 10 preloaded bands.24 The
cap is connected to the handle by a connecting wire or
string that runs through the instrument channel of the
endoscope. Once the bleeding lesion is suctioned into
the cap, rotation of the handle pulls the connecting wire,
leading to deployment of a band.25 Placement of a band
www.VideoGIE.org
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Figure 2. Over-the-scope (left) and Padlock (right) clips in deployed
conﬁguration. (Image used with permission form Gastrointest Endosc
2017;85:1087-92.)

at the base of the bleeding tissue causes mechanical
compression that leads to hemostasis and subsequent
thrombosis, necrosis, and sloughing.23
Covered self-expandable metallic stents. Covered
self-expandable metallic stents (CSEMSs) have been used for
the treatment of biliary and esophageal strictures for many
years.26 The use of CSEMSs as a salvage technique for hemostasis has been described.15 CSEMSs induce hemostasis by
mechanical tamponade of the bleeding vessel/lesion.

Topical hemostatic agents
Topical hemostatic agents are sprayed on the bleeding
site to achieve hemostasis. Three different topical hemostatic agents are commercially available, but only Hemospray (also known as TC-325; Cook Medical, WinstonSalem, NC, USA) is currently FDA cleared for use in the
United States.
Hemospray. Hemospray is an inorganic hemostatic
powder that was used by the military for bleeding control
before its introduction as an endoscopic hemostatic agent
for use in the GI tract.15,27 The Hemospray system consists
of a cartridge with an integrated handle connected to a delivery catheter. The handle houses the hemostatic powder,
a CO2 cartridge, a knob to activate the CO2 cartridge, a
valve to control the ﬂow of the powder, and a trigger button. The powder is sprayed toward the source of bleeding
through a 7F or 10F dedicated catheter, which is advanced
through the instrument channel of the endoscope.28 The
CO2 cartridge in the handle of the device is activated by
turning the activation knob. After a valve on the device is
opened, the trigger button allows the pressure generated
from the CO2 cartridge to propel the powder through
the catheter and onto the desired surface.29 Hemospray
is thought to cause hemostasis by sealing injured blood
vessels and activating platelets and the intrinsic
coagulation pathway.28,30,31 Use of the Hemospray device
is demonstrated in Video 2 (available online at www.
VideoGIE.org).

Ankaferd blood stopper
Ankaferd blood stopper (ABS) (Ankaferd Health Products Ltd, Istanbul, Turkey) is a medical plant extract that
www.VideoGIE.org

has historically been used as a hemostatic agent in Turkish
traditional medicine.32 It is in liquid form and is delivered
to the site of bleeding by a catheter, which is advanced
through the instrument channel of an endoscope.32
Various catheters can be used for this purpose. The
mechanism of action is not well understood, but it may
involve formation of an encapsulated protein mesh that
acts as an anchor for rapid erythrocyte aggregation.31,33,34
It may also inﬂuence angiogenesis and cellular
proliferation.31

EndoClot
EndoClot (EndoClot Plus Inc, Santa Clara, Calif, USA) is an
absorbable hemostatic polysaccharide powder derived from
plant starch.35 It is delivered to the site of bleeding with an
applicator system, which includes a delivery catheter and a
specially designed powder/air mixing chamber that is
connected to the powder container and an air compressor.
The delivery catheter is inserted into the instrument
channel of the endoscope and positioned toward the
bleeding lesion. Pressure from the air compressor propels
the powder through the catheter directly onto the
bleeding area.36 The mechanism of action is thought to
relate to formation of a gelled matrix that adheres to and
seals the bleeding tissue, along with absorption of water
from the blood, causing an increased concentration of
platelets, red blood cells, and coagulation proteins at the
bleeding site, with subsequent acceleration of the
physiologic clotting cascade.35

Endoscopic Doppler probe
Endoscopic Doppler probe (EDP) does not directly provide hemostasis, but it may assist the endoscopist in assessing the success or failure of endoscopic therapy.37 It may
also guide treatment and help predict the risk of
recurrent bleeding.38 EDP systems consist of a control
unit and a through-the-scope probe.39 Two EDP systems
are currently available for use in GI endoscopy: VTI
Endoscopic Doppler system (Vascular Technology Inc,
Lowell, Mass, USA), and the Endo-DOP system (DWL
GmbH, Singen, Germany).15 The VTI system uses a
disposable 20-MHz probe with a diameter of 1.5 mm and
lengths of 209 cm or 335 cm.40 The Endo-Dop system
uses a reusable 16-MHz probe with a diameter of 1.8 mm
and a length of 250 cm.41
The probe is advanced through the instrument channel
of the endoscope and applied to the bleeding site with
light-to-moderate pressure at multiple points, including
those immediately adjacent to any stigmata of bleeding.39
The auditory Doppler signal helps identify the presence
and course of bleeding vessels, which may not be visible.
Disappearance of the Doppler signal after treatment
indicates successful treatment of the bleeding lesion.
Bleeding lesions that remain Doppler positive after
treatment may be at increased risk of recurrent
hemorrhage.39,42
Volume 4, No. 7 : 2019 GASTROINTESTINAL ENDOSCOPY 291
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EUS-guided hemostasis
EUS-guided hemostasis is an emerging modality for control of bleeding lesions that are not readily accessible or are
refractory to standard endoscopic or interventional radiologic techniques.43 In those settings, EUS has been used
to inject various substances, deliver embolization coils, or
mark the location of the bleeding vessel.44 Most studies
assessing EUS for bleeding control in the GI tract involve
gastric variceal bleeding.15,44 Studies assessing the utility
of EUS for nonvariceal bleeding control are limited to small
case series and case reports.

OUTCOMES DATA
Injection therapy
Diluted epinephrine is the most commonly studied injectate for endoscopic treatment of nonvariceal GI
bleeding.45 Epinephrine injection therapy promotes
initial hemostasis, but this effect attenuates over time,
with subsequent risk of recurrent bleeding.46 In a metaanalysis of 19 RCTs in which epinephrine alone was
compared with combination therapy for control of
upper-GI bleeding (11 studies used a second injected
agent, 5 used clips, and 3 used a thermal method), the
risk of recurrent bleeding was signiﬁcantly lower in the
combination therapy groups than in the epinephrinealone group, regardless of which second modality was
applied (relative risk 0.53, 95% conﬁdence interval 0.35
to 0.81).47 Another meta-analysis of 16 studies reported
similar ﬁndings.48
In contrast to upper-GI bleeding (UGIB), randomized
comparative studies and meta-analyses evaluating injection
therapy in acute lower-GI bleeding (LGIB) are lacking.45
However, although data are limited, guidelines have
discouraged epinephrine monotherapy in LGIB.45
Although epinephrine injection can be used to gain
initial control of active bleeding and improve visualization
in nonvariceal upper- and lower-GI bleeding, it should be
combined with another method to decrease the risk of
recurrent bleeding.45,49

Thermal therapy
Multipolar electrocoagulation probe. In an RCT,
patients with peptic ulcer bleeding were assigned to
epinephrine injection followed by MPEC (n Z 58) or
MPEC alone (n Z 56).50 The rate of initial hemostasis
was signiﬁcantly higher and the required units of blood
signiﬁcantly lower in the combination therapy group.50
There was no signiﬁcant difference between the 2
treatment groups with respect to recurrent bleeding,
need for surgical intervention, or length of hospital stay.
In another RCT, patients with UGIB were randomized to
combination therapy with epinephrine injection and
MPEC (n Z 21), or monotherapy with clip placement
(n Z 26).51 Successful initial hemostasis, rate of
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recurrent bleeding, length of hospital stay, units of blood
transfused, surgery rates, and mortality were not different
between the 2 groups.51
In the lower-GI tract, a randomized study of 30 patients
with bleeding radiation proctopathy compared the effectiveness of MPEC (n Z 15) with APC (n Z 15).52
Although both modalities were equally effective for
treatment of the bleeding, the overall adverse event rate
including stenosis and pain was higher in the MPEC
group.52
Heater probe. Two RCTs have compared treatment
with heater probe to clip placement for nonvariceal
UGIB, with somewhat conﬂicting results.53,54 In 1 study,
113 patients were randomly assigned to receive treatment
with either heater probe (n Z 57) or clip (n Z 56) application.53 Initial hemostasis, 30-day mortality, and
emergency surgery rates were similar for both groups.
However, recurrent bleeding was signiﬁcantly higher in
the heater probe group (21% vs 1.8%; P < .05). Length
of hospital stay and transfusion requirements were
signiﬁcantly lower in the clip group.53 In the other RCT,
80 patients with peptic ulcer bleeding were randomized
to treatment with either heater probe (n Z 40) or clip
placement (n Z 40).54 The rate of initial hemostasis was
signiﬁcantly higher in the heater probe group than in the
clip group (100% vs 85%; P Z .01), whereas recurrent
bleeding rates were similar between the 2 groups.54
In a study of 93 patients with peptic ulcer bleeding, participants were randomized to receive either endoscopic
clip placement (n Z 46) or heater probe thermocoagulation plus epinephrine injection (n Z 47).55 Five patients
were excluded because of clip placement failure. Initial
hemostasis and recurrent bleeding rates were similar in
both groups.55 A meta-analysis of 15 RCTs (n Z 1156)
found thermocoagulation with MPEC or heater probe to
be equally effective as clip placement for treatment of nonvariceal UGIB.56
Hemostatic forceps. In a retrospective study of 39 patients with peptic ulcer bleeding (29 gastric, 10 duodenal),
initial hemostasis was achieved in 37 patients (95%) by use
of a monopolar hemostatic forceps. Recurrent bleeding
requiring treatment occurred in 2 patients.11 In a
prospective nonrandomized study, 50 patients with
nonvariceal UGIB underwent treatment by a bipolar
hemostatic forceps (27 patients) or clip placement (23
patients). Hemostasis was achieved in all patients who
underwent hemostatic forceps treatment, compared with
78% (18 of 23) of patients treated with clip placement
(P < .05).12 In a prospective noninferiority study,
patients with peptic ulcer bleeding were randomized to
receive either epinephrine injection plus APC (n Z 75)
or epinephrine injection plus soft coagulation with
monopolar hemostatic forceps (n Z 76).57 Hemostasis
was achieved in 96% of patients in both groups, and
there was no difference in the rate of recurrent bleeding
at 30 days.57
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Argon plasma coagulation. A meta-analysis of 2 RCTs
(n Z 121) comparing monotherapy with either APC or other
endoscopic hemostatic interventions (heater probe, injection
sclerotherapy) for treatment of peptic ulcer bleeding found
no signiﬁcant outcomes differences between the treatment
modalities.58 In an RCT of 116 patients with peptic ulcer
bleeding, patients were randomized to combined therapy
with distilled water injection plus APC (n Z 58) or distilled
water injection alone (n Z 58).59 Although initial
hemostasis rates were similar (97% vs 95%), the recurrent
bleeding rate was signiﬁcantly lower in the combination
therapy group (3.6% vs 16%, P Z .03).59
Three RCTs of comparable size (n Z 151 to n Z 185)
have evaluated the effectiveness of APC plus epinephrine
versus other modalities (heater probe, clip, hemostatic forceps) plus epinephrine for treatment of peptic ulcer
bleeding.57,60,61 In all 3 trials, there were no signiﬁcant differences between the 2 groups in terms of initial hemostasis (>95% in all treatment arms), recurrent bleeding, or
other relevant clinical outcomes.
Serial APC treatments in patients with bleeding gastric
antral vascular ectasia (GAVE) have been associated with
reduced transfusion requirements and improved hemoglobin levels.62-64 In an RCT of 88 cirrhotic patients with
GAVE, participants were randomized to endoscopic treatment with either EBL (n Z 44) or APC (n Z 44).65 The
number of sessions required for complete obliteration of
the lesions was lower with EBL therapy (2.98 sessions vs
3.48 sessions; P < .05). The EBL group also required
signiﬁcantly fewer blood transfusions. There were no
signiﬁcant differences in adverse event rates between the
2 groups.65 APC has shown effectiveness for treatment of
other types of UGIB including angioectasias, Dieulafoy
lesions, portal hypertensive gastropathy, and tumor
bleeding in small case series.66-69 In a Korean retrospective
series of 66 patients with obscure GI bleeding who underwent balloon enteroscopy and were found to have smallbowel angioectasias, 45 patients underwent endoscopic
treatment (APC in 87%), and 21 did not receive any endoscopic treatment.70 During a mean follow-up time of 24.5
months, the recurrent bleeding rates in the endoscopictreatment arm and no-treatment arm were 15.6% and
38.2% (P Z .059).
Multiple small studies and case series have reported a
reduction in rectal bleeding and transfusion requirements
and improvement in hemoglobin levels after serial treatments with APC for radiation proctopathy.71-74 One RCT
(n Z 30) found APC to be equally effective as MPEC,
with fewer adverse events for control of rectal bleeding
associated with radiation proctopathy.52 APC has also
been reported to be an effective treatment for bleeding
colonic angioectasias.75

Mechanical therapy
Through-the-scope clips. In a subgroup analysis
from a large meta-analysis (20 studies, n Z 2472) of
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patients with high-risk bleeding ulcers treated endoscopically, no combination of treatments was superior to mechanical therapy with hemostatic clips alone.76 Another
meta-analysis of 15 RCTs (n Z 1156) suggested that successful application of clips is superior to injection
therapy but comparable with thermocoagulation in producing deﬁnitive hemostasis in patients with nonvariceal
UGIB.56
Although no randomized studies have assessed the use
of TTS clips in LGIB, case series and reports have suggested the effectiveness of clips for this purpose.45,77 For
diverticular bleeding, endoscopic clips have been recommended to reduce the theoretic risk of transmural colonic
injury associated with contact thermal therapy.77 An RCT
(n Z 1499) did not ﬁnd prophylactic clipping to affect
the rate of postpolypectomy bleeding for polyps <2 cm
in diameter.78 A recent meta-analysis conﬁrmed these results and suggested that the use of prophylactic clip placement after polypectomy should not be a routine practice.79
However, prophylactic clip placement in certain high-risk
patients (eg, requiring anticoagulation, large and/or rightsided lesions) may be beneﬁcial, and this decision should
be individualized.80
Cap-mounted clips. In a retrospective study of 93 patients with 100 episodes of severe upper- (n Z 69) and
lower- (n Z 31) GI bleeding treated with the OTSC system,
immediate hemostasis and absence of in-hospital recurrent
bleeding were achieved in 88 of 100 (88%) and 78 of 100
(78%) patients, respectively.81 Other smaller studies have
shown similar results.82-85 Successful use of the Padlock
system to achieve hemostasis has been reported in 2
case series totaling 5 patients (1 bleeding rectal ulcer, 3
postpolypectomy bleeds, and 1 duodenal Dieulafoy
lesion).86,87
Endoscopic suturing. Outcomes data on the use of
the Overstitch device for hemostasis in the GI tract are
limited to a small case series of 3 patients with gastric ulcer
bleeding and a case report of bleeding anastomotic ulcer
after gastric bypass surgery.18,19 In all patients, bleeding
was controlled with the suturing device.
Banding devices. In a study of 88 cirrhotic patients
with GAVE who were randomized to EBL or APC, the number of sessions required for complete obliteration of the lesions and the number of required blood transfusions were
signiﬁcantly lower with EBL therapy.65 In a retrospective
analysis of a prospectively maintained endoscopic
database, outcomes from 24 patients with bleeding
duodenal Dieulafoy lesions were evaluated.88 After
treatment with EBL (n Z 11) or endoscopic clip
placement (n Z 13), primary hemostasis was achieved in
all patients. Recurrent bleeding was observed in 1 patient
(9.1%) from the EBL group and in 5 patients (38.5%)
from the clip group (P Z .166). There were no
differences in secondary outcomes between the 2
groups, including number of endoscopic sessions
required, need for angiographic embolization or
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emergent surgery, transfusion requirements, or length of
hospital stay.88 In a Japanese series of 53 patients with
colonic diverticular bleeding, EBL provided effective
hemostasis in 26 of 27 (96%) patients with active
hemorrhage or a nonbleeding visible vessel.89
Covered self-expandable metallic stents. The use
of CSEMSs for hemostasis in the GI tract has been studied
in a randomized controlled fashion only in the setting of
esophageal variceal bleeding.90 In the biliary tract,
successful use of CSEMSs for hemostasis has been
reported in cases of uncontrolled bleeding after
sphincterotomy, sphincteroplasty, intraductal biopsy, and
anastomotic stricture dilatation in posttransplantation
patients.91-94 Successful use of CSEMSs for hemostasis in
the esophagus, duodenum, and colon has also been
described in small case series and case reports.95-99

Topical hemostatic agents
Hemospray. Hemospray treatment was evaluated in a
French registry of 202 patients with UGIB of various causes
across 20 centers.100 Immediate hemostasis was achieved
in 195 of 202 patients (96.5%), independently of whether
it was used as ﬁrst-line therapy (91/94; 96.8%) or salvage
therapy (104/108; 96.3%). The type of lesion did not inﬂuence immediate hemostasis, which was achieved in 72 of
75 (96.0%) of ulcers, 58 of 61 (95.1%) of malignant lesions,
34 of 35 (97.1%) of postendoscopic bleeding, and 31 of 31
(100%) of bleeding from other causes.100 Recurrent
bleeding was noted at day 8 and day 30 in 26.7% and
33.5%, respectively. Other smaller studies have shown
similar results.101, 102 Use of Hemospray for control of
LGIB, early postoperative anastomotic bleeding, and postsphincterotomy bleeding has shown promise in case series
and case reports.28,103-105
Ankaferd blood stopper. In a retrospective case series of 26 patients with upper- and lower-GI bleeding of
various causes (including Mallory-Weiss tear, Dieulafoy
lesion, GAVE, radiation proctopathy, and postpolypectomy
bleeding), application of ABS provided hemostasis in all patients.32 Other case series and case reports have indicated
the effectiveness of ABS in the treatment of variceal
bleeding, tumor bleeding, postsphincterotomy bleeding,
and diverticular bleeding.106-109 Large prospective studies
are lacking.
EndoClot. In a prospective multicenter study of 70 patients, hemostasis was achieved in 30 of 47 (64%) patients
with UGIB treated with EndoClot as a ﬁrst-line therapy, 11
of 11 (100%) patients with UGIB treated with EndoClot as a
salvage therapy, and 10 of 12 (83%) patients with LGIB.110
In another study, LGIB after EMR was successfully
controlled with EndoClot in 18 of 20 (90%) lesions, with
no procedure-related adverse events.111
Endoscopic Doppler probe. In an RCT for the assessment of hemostasis in UGIB, 148 patients (125 with peptic
ulcers, 19 with Dieulafoy lesions, and 4 with Mallory Weiss
tears) were assigned to either standard (visually guided)
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endoscopic hemostasis (n Z 76) or hemostasis-assisted
by Doppler monitoring of blood ﬂow (n Z 72).39 The
primary outcome (recurrent bleeding within 30 days of
endoscopic hemostasis) occurred more frequently in the
control group (26.3%) than in the Doppler group (11.1%;
P Z .021).39 Other nonrandomized studies have also
suggested that Doppler probes can be of use for risk
stratiﬁcation of patients with UGIB, inasmuch as lack of a
Doppler signal after hemostasis indicates a reduced risk
of recurrent bleeding, whereas a persistently positive
signal is a marker for higher risk of recurrent
bleeding.38,112 Similar ﬁndings in a study of 38 patients
with diverticular bleeding suggest a potential risk stratiﬁcation role for EDP in LGIB as well.113
EUS-guided hemostasis. Use of EUS in the therapy of
nonvariceal GI bleeding is limited to small case series and
case reports. In a case series involving 17 patients with
nonvariceal GI bleeding of diverse causes, EUS was used
for either injection (eg, cyanoacrylate, ethanol), coil embolization, or tattooing the site of a subepithelial vessel for
subsequent EBL. In this series, EUS-directed therapy was
successful in 15 of 17 (88%) patients, with no further
bleeding over a median follow-up duration of 12 months.44
Other case series and reports have described similar
results.114-116

EASE OF USE
Many hemostatic devices require an adequate view of
the bleeding source and precise, en face positioning of
the endoscope to facilitate direct contact with the bleeding
lesion. In many cases, these conditions may not be easily
achievable. Noncontact hemostatic devices such as APC
and topical hemostatic agents obviate the need for some
of these conditions and are generally easier to use. Heater
probes and bipolar probes require adequate pressure on
the tissue and sufﬁcient duration of treatment to induce
coaptive coagulation. Both excessive pressure and duration
of treatment increase the risk of deep tissue injury and
perforation, whereas inadequate pressure or treatment
duration can exacerbate bleeding by unrooﬁng the
bleeding vessel.117
APC is a noncontact technique requiring an operative
distance from the probe tip to the tissue that ranges
from 2 to 8 mm.3 Longer distances hamper ignition of
the plasma, whereas probe contact with the tissue may
potentially cause ﬂow of argon gas into the submucosa,
leading to pneumatosis and rarely extraintestinal gas.118
Any liquid (eg, blood) between the probe tip and
bleeding tissue can induce the development of a
coagulation ﬁlm that can prevent adequate treatment of
the bleeding source.118
Deployment of TTS clips may be challenging through
an angulated endoscope or over a duodenoscope
elevator.3 TTS clips also may be difﬁcult to place on
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bleeding vessels within a large ﬁbrotic ulcer base because
there may be inadequate tissue to anchor the clip.3
Rotatable clips may permit easier alignment of the open
jaws with the bleeding vessel. Differences in the jaw
opening and the length of the tail of the clip may affect
performance in different anatomic locations. Potential
disadvantages of the cap-mounted clips include requirement for scope withdrawal to load the device, difﬁculty
in traversing the cricopharyngeus or luminal stenoses
with the mounted cap, and challenge in accessing certain
areas of the GI tract.21 In addition, cap-mounted clips are
difﬁcult to remove. Limitations of endoscopic suturing devices are lack of widespread availability, need for a
double-channel endoscope, technical complexity, and
restricted maneuverability, hindering access to some
areas of the GI tract.21
Advantages of topical hemostatic agents include ease
of application in a variety of locations and the potential
utility for treatment of many different bleeding lesions.30,119 Disadvantages of these agents include a transient reduction in endoscopic visualization and possible
interference with other treatment modalities if hemostasis should fail.30,119

SAFETY
Adverse events of injection therapy are usually related
to the substance injected rather than to the needle itself.3
Rare adverse events include tissue necrosis, ulceration,
and perforation, and also hypertension and cardiac
arrhythmia with epinephrine injection.120,121 Serious
adverse events of endoscopic thermal hemostasis
include uncontrollable bleeding and perforation.122
Pooled data from prospective controlled trials of bipolar
electrocoagulation and heater-probe therapy for peptic
ulcer hemostasis reported bleeding that required urgent
surgery in 5 of 1684 cases (0.3%) and perforation in 8 of
1684 cases (0.5%) .123 The risk of perforation may be
increased with retreatment after initial thermal
therapy.124 A meta-analysis of RCTs reported similar results.125 Adverse events from APC are rare and include
distention of the GI tract with argon gas, submucosal
emphysema, pneumomediastinum, pneumoperitoneum,
and perforation.3 Intracolonic gas explosion with
inadequate colonic cleansing has been described; as
such, complete colonic cleansing is recommended before
use of APC in the colon.118 Clip deployment failure has
been described at certain locations in the GI tract,
particularly the posterior wall of the duodenal bulb.56
Perforation from clip placement has been reported but is
exceedingly rare.126 The reported adverse events
associated with topical hemostatic agents are primarily
technical in nature, including occlusion of the spray
catheter or instrument channel.126
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FINANCIAL CONSIDERATIONS
List prices of commonly used hemostatic devices in the
United States are shown in Tables 1 through 4. Device
costs for most clinical enterprises will be lower than list
prices owing to purchasing agreements. Current
Procedural Terminology (CPT) codes for endoscopic
hemostasis, any method, include the following: 43227
(esophagoscopy), 43255 (EGD), 44366 (enteroscopy not
including ileum), 44378 (enteroscopy including ileum),
44391 (colonoscopy through stoma), 45334 (ﬂexible
sigmoidoscopy), and 45382 (colonoscopy). When CPT
codes are used for nonvariceal bleeding, additional codes
for injection or EBL are not concomitantly reported.

AREAS FOR FUTURE RESEARCH
Topical hemostatic agents such as Hemospray are
promising treatments for GI bleeding. Comparative studies
between these agents and other conventional modalities
would be useful to better deﬁne their clinical role. Capmounted clips may be particularly useful in refractory
bleeding because they allow ligation of larger vessels and
may be less hindered by ﬁbrotic tissue than TTS clips.
Further clinical experience will serve to better deﬁne the
bleeding lesions and the anatomic locations that are best
served by cap-mounted clips. The presently available
endoscopic suturing system is restricted to use with a
double-channel endoscope, but a suturing platform is in
development for use with standard endoscopes and thus
may potentially have broader applicability. Although hemostatic forceps have been used primarily for the prevention
and treatment of bleeding during endoscopic resection,
their use as therapy for noniatrogenic GI bleeding should
be further evaluated.

SUMMARY
Endoscopic evaluation and treatment remain a cornerstone in the management of nonvariceal upper- and
lower-GI bleeding. A variety of devices are available for hemostasis of bleeding lesions in the GI tract. Other than injection therapy, which should not be used as
monotherapy, there are few compelling data that strongly
favor any one device over another. For endoscopists, the
choice of a hemostatic device should depend on the
type and location of the bleeding lesion, the availability
of equipment and expertise, and the cost of the device.
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